MAP2K7 and melanoma: BRAF codon V600 activating mutations, which affect almost a half of melanoma patients, became a therapeutic target with the development of specific inhibitors—namely BRAF and MEK inhibitors—which are currently used in both adjuvant and metastatic settings [108].